NKILT Therapeutics announces oral presentation featuring Chimeric ILT-Receptor (CIR™) engineered NK cells at the 65th ASH Annual Meeting and poster presentation at the 38th SITC Annual Meeting
/PRNewswire/ -- NKILT Therapeutics, Inc., a preclinical-stage cell therapy biotech company developing proprietary Chimeric ILT-Receptor (CIR™)–engineered...
Source: prnewswire.com